UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.14
+0.76 (7.32%)
At close: May 12, 2025, 4:00 PM
11.50
+0.36 (3.23%)
After-hours: May 12, 2025, 7:52 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 36.75, with a low estimate of 16 and a high estimate of 55. The average target predicts an increase of 229.89% from the current stock price of 11.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +124.42% | May 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +124.42% | May 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +393.72% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +124.42% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
122.99M
from 90.40M
Increased by 36.05%
Revenue Next Year
263.86M
from 122.99M
Increased by 114.54%
EPS This Year
-2.97
from -2.96
EPS Next Year
-0.68
from -2.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 144.4M | 411.1M | 741.7M | ||
| Avg | 123.0M | 263.9M | 405.2M | ||
| Low | 106.0M | 168.1M | 235.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 234.2% | 181.1% | ||
| Avg | 36.1% | 114.5% | 53.6% | ||
| Low | 17.2% | 36.7% | -10.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.80 | 2.14 | 4.24 | ||
| Avg | -2.97 | -0.68 | 1.62 | ||
| Low | -3.64 | -2.35 | -0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.